Biocompatible Solutions and Long-Term Changes in Peritoneal Solute Transport
The inflammation-driven increase in peritoneal solute transport rate that occurs during long-term peritoneal dialysis is associated with higher mortality, hospitalization, and encapsulating peritoneal sclerosis. Because biocompatible solutions were developed to mitigate these effects, we examined th...
Gespeichert in:
| Veröffentlicht in: | Clinical journal of the American Society of Nephrology 2018-10, Vol.13 (10), p.1526-1533 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1533 |
|---|---|
| container_issue | 10 |
| container_start_page | 1526 |
| container_title | Clinical journal of the American Society of Nephrology |
| container_volume | 13 |
| creator | Elphick, Emma H Teece, Lucy Chess, James A Do, Jun-Young Kim, Yong-Lim Lee, H Bahl Davison, Sara N Topley, Nicholas Davies, Simon J Lambie, Mark |
| description | The inflammation-driven increase in peritoneal solute transport rate that occurs during long-term peritoneal dialysis is associated with higher mortality, hospitalization, and encapsulating peritoneal sclerosis. Because biocompatible solutions were developed to mitigate these effects, we examined the association with their use and longitudinal peritoneal solute transport rate.
We analyzed subjects from the multinational prospective Global Fluid Study with three or more peritoneal solute transport rate measurements >2 months from the start of peritoneal dialysis. Follow-up was for 7.5 years (median, 2.3 years; interquartile range, 1.8-3.6) in biocompatible solutions and 12.8 years (median, 3.2 years; interquartile range, 1.9-4.3) for standard solutions. Using a random intercept/slopes multilevel model, we examined the association of patients using biocompatible solutions and peritoneal solute transport rate over time, adjusting for center effects, dialysate dextrose concentration, baseline dialysate IL-6 concentration, icodextrin use, residual kidney function, and peritonitis.
Of 366 patients, the 71 receiving biocompatible solutions throughout their time on peritoneal dialysis had a mean adjusted dialysate-to-plasma creatinine ratio of 0.67 compared with 0.72 for standard solutions (
=0.02). With duration of treatment, there was a continuous increase in peritoneal solute transport rate in patients using standard solutions (range, 2 months to 4 years). In contrast, patients using biocompatible solutions had peritoneal solute transport rates that plateaued after 2 years of therapy. These changes in peritoneal solute transport rate were independent of baseline inflammation and time-varying predictors of faster peritoneal solute transport rate. In patients suffering episodes of peritonitis while using standard solutions, there was an associated increase in peritoneal solute transport rate of 0.020 (95% confidence interval, 0.01 to 0.03) per episode, whereas in patients using biocompatible solutions, there was no change in this parameter (-0.014; 95% confidence interval, -0.03 to |
| doi_str_mv | 10.2215/CJN.02380218 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6218832</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2098769025</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-2eabe9361b93890d9c26d6a7fc4d5183511980806ec3efe604183ab9a4d9e69d3</originalsourceid><addsrcrecordid>eNpVkc1LxDAQxYMo7rp68yw9erBrPppuchG0-ElRwRW8hbSd3Y20SU1awf_eyq6LnmZgfryZeQ-hY4KnlBJ-nj08TjFlAlMidtCYcM5jifnb7rZPyAgdhPCOcZIwyvfRiGEyI5jjMcqvjCtd0-rOFDVEL67uO-NsiLStotzZZTwH30TZStslhMjY6Bm86ZwFXa9piOZe29A63x2ivYWuAxxt6gS93lzPs7s4f7q9zy7zuGQi6WIKugDJUlJIJiSuZEnTKtWzRZlUnAjGCZECC5xCyWAB6fCAYLqQOqkkpLJiE3Sx1m37ooGqBNt5XavWm0b7L-W0Uf8n1qzU0n2qdPBIMDoInG4EvPvoIXSqMaGEutYWXB8UxVLMUokpH9CzNVp6F4KHxXYNweonADUEoH4DGPCTv6dt4V_H2TdZhIGc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2098769025</pqid></control><display><type>article</type><title>Biocompatible Solutions and Long-Term Changes in Peritoneal Solute Transport</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Elphick, Emma H ; Teece, Lucy ; Chess, James A ; Do, Jun-Young ; Kim, Yong-Lim ; Lee, H Bahl ; Davison, Sara N ; Topley, Nicholas ; Davies, Simon J ; Lambie, Mark</creator><creatorcontrib>Elphick, Emma H ; Teece, Lucy ; Chess, James A ; Do, Jun-Young ; Kim, Yong-Lim ; Lee, H Bahl ; Davison, Sara N ; Topley, Nicholas ; Davies, Simon J ; Lambie, Mark</creatorcontrib><description>The inflammation-driven increase in peritoneal solute transport rate that occurs during long-term peritoneal dialysis is associated with higher mortality, hospitalization, and encapsulating peritoneal sclerosis. Because biocompatible solutions were developed to mitigate these effects, we examined the association with their use and longitudinal peritoneal solute transport rate.
We analyzed subjects from the multinational prospective Global Fluid Study with three or more peritoneal solute transport rate measurements >2 months from the start of peritoneal dialysis. Follow-up was for 7.5 years (median, 2.3 years; interquartile range, 1.8-3.6) in biocompatible solutions and 12.8 years (median, 3.2 years; interquartile range, 1.9-4.3) for standard solutions. Using a random intercept/slopes multilevel model, we examined the association of patients using biocompatible solutions and peritoneal solute transport rate over time, adjusting for center effects, dialysate dextrose concentration, baseline dialysate IL-6 concentration, icodextrin use, residual kidney function, and peritonitis.
Of 366 patients, the 71 receiving biocompatible solutions throughout their time on peritoneal dialysis had a mean adjusted dialysate-to-plasma creatinine ratio of 0.67 compared with 0.72 for standard solutions (
=0.02). With duration of treatment, there was a continuous increase in peritoneal solute transport rate in patients using standard solutions (range, 2 months to 4 years). In contrast, patients using biocompatible solutions had peritoneal solute transport rates that plateaued after 2 years of therapy. These changes in peritoneal solute transport rate were independent of baseline inflammation and time-varying predictors of faster peritoneal solute transport rate. In patients suffering episodes of peritonitis while using standard solutions, there was an associated increase in peritoneal solute transport rate of 0.020 (95% confidence interval, 0.01 to 0.03) per episode, whereas in patients using biocompatible solutions, there was no change in this parameter (-0.014; 95% confidence interval, -0.03 to <0.01).
These data suggest that a different temporal pattern in changes in peritoneal solute transport rate occurs during the course of peritoneal dialysis according to solution type and that patients using biocompatible solutions may avoid the increase in solute transport associated with peritonitis.</description><identifier>ISSN: 1555-9041</identifier><identifier>EISSN: 1555-905X</identifier><identifier>DOI: 10.2215/CJN.02380218</identifier><identifier>PMID: 30171050</identifier><language>eng</language><publisher>United States: American Society of Nephrology</publisher><subject>Biological Transport ; Dialysis Solutions - metabolism ; Female ; Humans ; Male ; Middle Aged ; Original ; Peritoneal Dialysis ; Peritoneum - metabolism ; Prospective Studies ; Time Factors</subject><ispartof>Clinical journal of the American Society of Nephrology, 2018-10, Vol.13 (10), p.1526-1533</ispartof><rights>Copyright © 2018 by the American Society of Nephrology.</rights><rights>Copyright © 2018 by the American Society of Nephrology 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-2eabe9361b93890d9c26d6a7fc4d5183511980806ec3efe604183ab9a4d9e69d3</citedby><cites>FETCH-LOGICAL-c384t-2eabe9361b93890d9c26d6a7fc4d5183511980806ec3efe604183ab9a4d9e69d3</cites><orcidid>0000-0001-8805-6962 ; 0000-0003-2925-4779 ; 0000-0001-5127-4755 ; 0000-0002-6285-5368</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218832/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218832/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30171050$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Elphick, Emma H</creatorcontrib><creatorcontrib>Teece, Lucy</creatorcontrib><creatorcontrib>Chess, James A</creatorcontrib><creatorcontrib>Do, Jun-Young</creatorcontrib><creatorcontrib>Kim, Yong-Lim</creatorcontrib><creatorcontrib>Lee, H Bahl</creatorcontrib><creatorcontrib>Davison, Sara N</creatorcontrib><creatorcontrib>Topley, Nicholas</creatorcontrib><creatorcontrib>Davies, Simon J</creatorcontrib><creatorcontrib>Lambie, Mark</creatorcontrib><title>Biocompatible Solutions and Long-Term Changes in Peritoneal Solute Transport</title><title>Clinical journal of the American Society of Nephrology</title><addtitle>Clin J Am Soc Nephrol</addtitle><description>The inflammation-driven increase in peritoneal solute transport rate that occurs during long-term peritoneal dialysis is associated with higher mortality, hospitalization, and encapsulating peritoneal sclerosis. Because biocompatible solutions were developed to mitigate these effects, we examined the association with their use and longitudinal peritoneal solute transport rate.
We analyzed subjects from the multinational prospective Global Fluid Study with three or more peritoneal solute transport rate measurements >2 months from the start of peritoneal dialysis. Follow-up was for 7.5 years (median, 2.3 years; interquartile range, 1.8-3.6) in biocompatible solutions and 12.8 years (median, 3.2 years; interquartile range, 1.9-4.3) for standard solutions. Using a random intercept/slopes multilevel model, we examined the association of patients using biocompatible solutions and peritoneal solute transport rate over time, adjusting for center effects, dialysate dextrose concentration, baseline dialysate IL-6 concentration, icodextrin use, residual kidney function, and peritonitis.
Of 366 patients, the 71 receiving biocompatible solutions throughout their time on peritoneal dialysis had a mean adjusted dialysate-to-plasma creatinine ratio of 0.67 compared with 0.72 for standard solutions (
=0.02). With duration of treatment, there was a continuous increase in peritoneal solute transport rate in patients using standard solutions (range, 2 months to 4 years). In contrast, patients using biocompatible solutions had peritoneal solute transport rates that plateaued after 2 years of therapy. These changes in peritoneal solute transport rate were independent of baseline inflammation and time-varying predictors of faster peritoneal solute transport rate. In patients suffering episodes of peritonitis while using standard solutions, there was an associated increase in peritoneal solute transport rate of 0.020 (95% confidence interval, 0.01 to 0.03) per episode, whereas in patients using biocompatible solutions, there was no change in this parameter (-0.014; 95% confidence interval, -0.03 to <0.01).
These data suggest that a different temporal pattern in changes in peritoneal solute transport rate occurs during the course of peritoneal dialysis according to solution type and that patients using biocompatible solutions may avoid the increase in solute transport associated with peritonitis.</description><subject>Biological Transport</subject><subject>Dialysis Solutions - metabolism</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original</subject><subject>Peritoneal Dialysis</subject><subject>Peritoneum - metabolism</subject><subject>Prospective Studies</subject><subject>Time Factors</subject><issn>1555-9041</issn><issn>1555-905X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkc1LxDAQxYMo7rp68yw9erBrPppuchG0-ElRwRW8hbSd3Y20SU1awf_eyq6LnmZgfryZeQ-hY4KnlBJ-nj08TjFlAlMidtCYcM5jifnb7rZPyAgdhPCOcZIwyvfRiGEyI5jjMcqvjCtd0-rOFDVEL67uO-NsiLStotzZZTwH30TZStslhMjY6Bm86ZwFXa9piOZe29A63x2ivYWuAxxt6gS93lzPs7s4f7q9zy7zuGQi6WIKugDJUlJIJiSuZEnTKtWzRZlUnAjGCZECC5xCyWAB6fCAYLqQOqkkpLJiE3Sx1m37ooGqBNt5XavWm0b7L-W0Uf8n1qzU0n2qdPBIMDoInG4EvPvoIXSqMaGEutYWXB8UxVLMUokpH9CzNVp6F4KHxXYNweonADUEoH4DGPCTv6dt4V_H2TdZhIGc</recordid><startdate>20181008</startdate><enddate>20181008</enddate><creator>Elphick, Emma H</creator><creator>Teece, Lucy</creator><creator>Chess, James A</creator><creator>Do, Jun-Young</creator><creator>Kim, Yong-Lim</creator><creator>Lee, H Bahl</creator><creator>Davison, Sara N</creator><creator>Topley, Nicholas</creator><creator>Davies, Simon J</creator><creator>Lambie, Mark</creator><general>American Society of Nephrology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8805-6962</orcidid><orcidid>https://orcid.org/0000-0003-2925-4779</orcidid><orcidid>https://orcid.org/0000-0001-5127-4755</orcidid><orcidid>https://orcid.org/0000-0002-6285-5368</orcidid></search><sort><creationdate>20181008</creationdate><title>Biocompatible Solutions and Long-Term Changes in Peritoneal Solute Transport</title><author>Elphick, Emma H ; Teece, Lucy ; Chess, James A ; Do, Jun-Young ; Kim, Yong-Lim ; Lee, H Bahl ; Davison, Sara N ; Topley, Nicholas ; Davies, Simon J ; Lambie, Mark</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-2eabe9361b93890d9c26d6a7fc4d5183511980806ec3efe604183ab9a4d9e69d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Biological Transport</topic><topic>Dialysis Solutions - metabolism</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original</topic><topic>Peritoneal Dialysis</topic><topic>Peritoneum - metabolism</topic><topic>Prospective Studies</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Elphick, Emma H</creatorcontrib><creatorcontrib>Teece, Lucy</creatorcontrib><creatorcontrib>Chess, James A</creatorcontrib><creatorcontrib>Do, Jun-Young</creatorcontrib><creatorcontrib>Kim, Yong-Lim</creatorcontrib><creatorcontrib>Lee, H Bahl</creatorcontrib><creatorcontrib>Davison, Sara N</creatorcontrib><creatorcontrib>Topley, Nicholas</creatorcontrib><creatorcontrib>Davies, Simon J</creatorcontrib><creatorcontrib>Lambie, Mark</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical journal of the American Society of Nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Elphick, Emma H</au><au>Teece, Lucy</au><au>Chess, James A</au><au>Do, Jun-Young</au><au>Kim, Yong-Lim</au><au>Lee, H Bahl</au><au>Davison, Sara N</au><au>Topley, Nicholas</au><au>Davies, Simon J</au><au>Lambie, Mark</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biocompatible Solutions and Long-Term Changes in Peritoneal Solute Transport</atitle><jtitle>Clinical journal of the American Society of Nephrology</jtitle><addtitle>Clin J Am Soc Nephrol</addtitle><date>2018-10-08</date><risdate>2018</risdate><volume>13</volume><issue>10</issue><spage>1526</spage><epage>1533</epage><pages>1526-1533</pages><issn>1555-9041</issn><eissn>1555-905X</eissn><abstract>The inflammation-driven increase in peritoneal solute transport rate that occurs during long-term peritoneal dialysis is associated with higher mortality, hospitalization, and encapsulating peritoneal sclerosis. Because biocompatible solutions were developed to mitigate these effects, we examined the association with their use and longitudinal peritoneal solute transport rate.
We analyzed subjects from the multinational prospective Global Fluid Study with three or more peritoneal solute transport rate measurements >2 months from the start of peritoneal dialysis. Follow-up was for 7.5 years (median, 2.3 years; interquartile range, 1.8-3.6) in biocompatible solutions and 12.8 years (median, 3.2 years; interquartile range, 1.9-4.3) for standard solutions. Using a random intercept/slopes multilevel model, we examined the association of patients using biocompatible solutions and peritoneal solute transport rate over time, adjusting for center effects, dialysate dextrose concentration, baseline dialysate IL-6 concentration, icodextrin use, residual kidney function, and peritonitis.
Of 366 patients, the 71 receiving biocompatible solutions throughout their time on peritoneal dialysis had a mean adjusted dialysate-to-plasma creatinine ratio of 0.67 compared with 0.72 for standard solutions (
=0.02). With duration of treatment, there was a continuous increase in peritoneal solute transport rate in patients using standard solutions (range, 2 months to 4 years). In contrast, patients using biocompatible solutions had peritoneal solute transport rates that plateaued after 2 years of therapy. These changes in peritoneal solute transport rate were independent of baseline inflammation and time-varying predictors of faster peritoneal solute transport rate. In patients suffering episodes of peritonitis while using standard solutions, there was an associated increase in peritoneal solute transport rate of 0.020 (95% confidence interval, 0.01 to 0.03) per episode, whereas in patients using biocompatible solutions, there was no change in this parameter (-0.014; 95% confidence interval, -0.03 to <0.01).
These data suggest that a different temporal pattern in changes in peritoneal solute transport rate occurs during the course of peritoneal dialysis according to solution type and that patients using biocompatible solutions may avoid the increase in solute transport associated with peritonitis.</abstract><cop>United States</cop><pub>American Society of Nephrology</pub><pmid>30171050</pmid><doi>10.2215/CJN.02380218</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-8805-6962</orcidid><orcidid>https://orcid.org/0000-0003-2925-4779</orcidid><orcidid>https://orcid.org/0000-0001-5127-4755</orcidid><orcidid>https://orcid.org/0000-0002-6285-5368</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1555-9041 |
| ispartof | Clinical journal of the American Society of Nephrology, 2018-10, Vol.13 (10), p.1526-1533 |
| issn | 1555-9041 1555-905X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6218832 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Biological Transport Dialysis Solutions - metabolism Female Humans Male Middle Aged Original Peritoneal Dialysis Peritoneum - metabolism Prospective Studies Time Factors |
| title | Biocompatible Solutions and Long-Term Changes in Peritoneal Solute Transport |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T02%3A21%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biocompatible%20Solutions%20and%20Long-Term%20Changes%20in%20Peritoneal%20Solute%20Transport&rft.jtitle=Clinical%20journal%20of%20the%20American%20Society%20of%20Nephrology&rft.au=Elphick,%20Emma%20H&rft.date=2018-10-08&rft.volume=13&rft.issue=10&rft.spage=1526&rft.epage=1533&rft.pages=1526-1533&rft.issn=1555-9041&rft.eissn=1555-905X&rft_id=info:doi/10.2215/CJN.02380218&rft_dat=%3Cproquest_pubme%3E2098769025%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2098769025&rft_id=info:pmid/30171050&rfr_iscdi=true |